Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for sofosbuvir, daclatasvir and ribavirin

  1. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C

    Technology appraisal guidance
    Published
    25 November 2015
    View recommendations

    Sections for TA363

  2. Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

    Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    25 January 2017
    View recommendations

    Sections for TA430

  3. Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)

    Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    24 January 2018
    View recommendations

    Sections for TA499

  4. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.

    Technology appraisal guidance
    Published
    25 November 2015
    View recommendations

    Sections for TA365

  5. Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

    Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    26 October 2016
    View recommendations

    Sections for TA413